PTC Therapeutics won a competitive bankruptcy auction for Sangamo’s Fabry gene therapy candidate ST-920 (isaralgagene civaparvovec). Under the deal, Sangamo is set to receive $111 million upfront, plus up to $100 million in regulatory milestone payments. The transaction gives PTC a BLA-ready one-time AAV gene therapy designed to restore alpha-galactosidase A production in patients with Fabry disease. Phase I/II STAAR data reportedly show the therapy’s ability to shift off enzyme replacement therapy after dosing, supporting continued development toward potential regulatory clearance. For the rare-disease pipeline, the auction signals that strategic acquirers are willing to step into programs where regulatory pathways may be clearer but execution and commercialization carry higher execution risk. The PTC acquisition also reframes Sangamo’s post-bankruptcy asset strategy after the company began selling assets following its June Chapter 11 filing.